Crispr Therapeutics AG (CRSP)

[jondoeuk]

ASH abstracts

4629 CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study https://ash.confex.com/ash/2022/webprogram/Paper166432.html

2137 Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent ß-Thalassemia https://ash.confex.com/ash/2022/webprogram/Paper166881.html

12 Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease https://ash.confex.com/ash/2022/webprogram/Paper162353.html